DGY0FZZ
Other Radiation Pituitary Gland to None with None, Plaque Radiation Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | G Endocrine System |
| Operation | Y Other Radiation |
| Body Part | 0 Pituitary Gland |
| Approach | F Plaque Radiation |
| Device | Z None |
| Qualifier | Z None |
Procedure Overview
This family covers radiation treatments delivered to the endocrine system through means other than an external beam or an implanted brachytherapy source - most often the administration of a radioactive isotope that the target gland absorbs on its own. The best-known example is radioactive iodine (I-131) therapy for the thyroid: because thyroid tissue naturally takes up iodine, a swallowed or infused dose concentrates in thyroid cells and delivers radiation from within, sparing most surrounding tissue. It is used to shrink an overactive thyroid in hyperthyroidism or Graves' disease, and to destroy residual or metastatic thyroid cancer cells after a gland has been surgically removed.
Because the isotope circulates briefly before concentrating in the gland, patients are typically asked to follow radiation precautions for a period afterward, limiting close contact with others, particularly children and pregnant people. The treatment is usually outpatient for lower doses and may require a brief inpatient isolation stay for higher therapeutic doses used against thyroid cancer.
Anatomy & Axis Detail
Pituitary Gland
The pituitary gland occasionally receives radiation delivery methods that fall outside standard external beam, brachytherapy, or stereotactic radiosurgery categories, such as proton beam therapy or other specialized modalities used to treat adenomas or residual tumor when conventional techniques are unsuitable due to tumor shape, prior treatment history, or proximity to critical structures like the optic chiasm and cavernous sinus. These alternative approaches are chosen for their distinct dose distribution properties, such as proton therapy's sharp distal dose falloff, which can better spare surrounding brain tissue in select cases. Because the pituitary's function governs multiple hormone axes, treatment planning must weigh the risk of hypopituitarism against tumor control, and documentation should specify the particular modality used since it does not fit the more commonly coded radiation techniques.
Modality Qualifier: Plaque Radiation
Plaque Radiation refers to treatment using a radioactive plaque, most commonly an episcleral plaque sutured onto the eye, to deliver localized brachytherapy to ocular tumors such as choroidal melanoma. It is a surface-applied, sustained-contact technique distinct from Contact Radiation's brief external application and from High or Low Dose Rate brachytherapy performed with afterloading applicators elsewhere in the body.
Coding & Documentation
A coder should confirm the specific isotope, dose, and delivery route documented by the treating physician, since this determines the body part and qualifier values within the family rather than a generic radiation order. Documentation should state the target gland or structure, the isotope used, and confirm that the treatment was systemic uptake-based rather than a directed beam or implanted source - that distinction is what separates this code from the Beam Radiation and Brachytherapy families in the same body system. A frequent error is defaulting to a beam radiation code because radiation oncology performed the treatment, when the actual modality documented is isotope administration; the technique described in the note, not the ordering department, governs code selection. Coders should also verify whether the encounter is for treatment of malignancy versus benign hyperthyroidism, since this affects reporting elsewhere in the record even though it does not change the procedure code itself.
Commonly Confused With
This family is most often confused with D|G|0 (Beam Radiation to the endocrine system), which involves an external machine directing radiation at the gland from outside the body rather than a systemically absorbed isotope. It can also be confused with nuclear medicine diagnostic imaging codes that use similar isotopes in tracer doses for thyroid scans - the distinguishing factor is therapeutic intent and dose versus diagnostic imaging intent, which should be explicit in the physician's order and note.